Driehaus Capital Management Adds $10M in Edgewise Therapeutics, Inc. ($EWTX)
Key Points
- Driehaus Capital Management changed its Edgewise Therapeutics, Inc. ($EWTX) stake by 6.8% last quarter, boosting to 4,477,942 shares worth $155.97 million.
- Wall Street's consensus rating on $EWTX is Buy and an average price target of $46.08.
- $EWTX last traded around $34.83.
Driehaus Capital Management increased its position in Edgewise Therapeutics, Inc. ($EWTX) by 6.8% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,477,942 shares of Edgewise Therapeutics, Inc. after buying 286,749 shares during the quarter. Driehaus Capital Management's holdings in Edgewise Therapeutics, Inc. were worth $155.97 million as of its most recent filing.
Edgewise Therapeutics, Inc. ($EWTX) Stock
Edgewise Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.